Only one drug is currently approved to treat sickle cell disease, but a small study at the University of North Carolina at Chapel Hill School of Medicine suggests that an intravenous blood thinner, widely used in patients with acute heart problems and during coronary artery stent placement, might become a new therapy for people with this painful disorder.
